Marc Spentchian

1.0k total citations
12 papers, 387 citations indexed

About

Marc Spentchian is a scholar working on Genetics, Hematology and Rheumatology. According to data from OpenAlex, Marc Spentchian has authored 12 papers receiving a total of 387 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Genetics, 7 papers in Hematology and 5 papers in Rheumatology. Recurrent topics in Marc Spentchian's work include Chronic Lymphocytic Leukemia Research (7 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Acute Myeloid Leukemia Research (3 papers). Marc Spentchian is often cited by papers focused on Chronic Lymphocytic Leukemia Research (7 papers), Chronic Myeloid Leukemia Treatments (6 papers) and Acute Myeloid Leukemia Research (3 papers). Marc Spentchian collaborates with scholars based in France, United Kingdom and United States. Marc Spentchian's co-authors include Philippe Rousselot, Victoria Raggueneau, Sylvie Castaigné, Gérald Massonnet, Christine Chomienne, Joseph Saliba, Jean-Paul Beressi, Benjamin Manéglier, Els Verhoeyen and Stany Chrétien and has published in prestigious journals such as Nature, Blood and The American Journal of Cardiology.

In The Last Decade

Marc Spentchian

12 papers receiving 381 citations

Peers

Countries citing papers authored by Marc Spentchian

Since Specialization

Citations

This map shows the geographic impact of Marc Spentchian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc Spentchian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc Spentchian more than expected).

Fields of papers citing papers by Marc Spentchian

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc Spentchian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc Spentchian. The network helps show where Marc Spentchian may publish in the future.

Co-authorship network of co-authors of Marc Spentchian

This figure shows the co-authorship network connecting the top 25 collaborators of Marc Spentchian. A scholar is included among the top collaborators of Marc Spentchian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc Spentchian. Marc Spentchian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

#	Work	Indexed citations
1	Leon's helmet 2022 ·Haematologica ·(unknown), Alice Marceau‐Renaut, Marc Spentchian, (unknown), (unknown)	1
2	A third anti-SARS-CoV-2 mRNA dose does not overcome the pejorative impact of anti-CD20 therapy and/or low immunoglobulin levels in patients with lymphoma or chronic lymphocytic leukemia 2021 ·Haematologica ·Milena Kohn, Marc Delord, (unknown), (unknown), Fatiha Merabet, (unknown), (unknown), H. Farhat, (unknown), Aurélie Cabannes‐Hamy, Juliette Lambert, Stéphanie Marque‐Juillet, Victoria Raggueneau, (unknown), Marc Spentchian, Sophie Rigaudeau, Philippe Rousselot, Caroline Besson	10
3	A Third Anti-Sars-Cov2 mRNA Dose Does Not Overcome the Pejorative Impact of Anti-CD20 Therapy and/or Low Immunoglobulin Level in CLL/Lymphoma Patients 2021 ·Blood ·(unknown), Milena Kohn, Fatiha Merabet, (unknown), (unknown), (unknown), Stéphanie Marque‐Juillet, Victoria Raggueneau, (unknown), Marc Spentchian, Marc Delord, Sophie Rigaudeau, Caroline Besson	1
4	Late molecular recurrences in patients with chronic myeloid leukemia experiencing treatment-free remission 2020 ·Blood Advances ·Philippe Rousselot, (unknown), Marc Delord, Jean Michel Cayuela, Marc Spentchian	35
5	A Report on 114 Patients Who Experienced Treatment Free Remission in a Single Institution during a 15 Years Period: Long Term Follow-up, Late Molecular Relapses and Second Attempts 2019 ·Blood ·Philippe Rousselot, (unknown), Marc Delord, Caroline Besson, Jean‐Michel Cayuela, Marc Spentchian	7
6	Azacytidine in combination with tyrosine kinase inhibitors induced durable responses in patients with advanced phase chronic myelogenous leukemia 2017 ·Leukemia & lymphoma ·(unknown), (unknown), David Ghez, Pascale Cony‐Makhoul, (unknown), (unknown), (unknown), (unknown), (unknown), H. Farhat, Sophie Rigaudeau, Noémie de Gunzburg, (unknown), Christine Terré, Victoria Raggueneau, (unknown), Marc Spentchian, Stéphane de Botton, Philippe Rousselot	15
7	Erosion of the chronic myeloid leukaemia stem cell pool by PPARγ agonists 2015 ·Nature ·Stéphane Prost, Francis Relouzat, Marc Spentchian, (unknown), Joseph Saliba, Gérald Massonnet, Jean-Paul Beressi, Els Verhoeyen, Victoria Raggueneau, Benjamin Manéglier, Sylvie Castaigné, Christine Chomienne, Stany Chrétien, Philippe Rousselot, Philippe Leboulch	218
8	GATA2 Expression Level in Chronic Myeloid Leukemia (CML) Patients Correlates with Their Prognostic Scores and Is Associated with Disease Stage at Diagnosis 2015 ·Blood ·Philippe Guardiola, Corentin Orvain, Nicholas C.P. Cross, Martine Gardembas, Marc Spentchian, (unknown), Diane K. Lambert, (unknown), Anne Bouvier, Odile Blanchet, (unknown), Norbert Ifrah, Frank Giles, Andreas Hochhaus, Jerald P. Radich, Philippe Rousselot	1
9	Clinical efficacy of second generation tyrosine kinase inhibitor and 5-azacytidine combination in chronic myelogenous leukaemia in myeloid blast crisis 2013 ·European Journal of Cancer ·David Ghez, Jean‐Baptiste Micol, Florence Pasquier, Nathalie Auger, Véronique Saada, Marc Spentchian, Jean‐Christophe Ianotto, Jean Bourhis, (unknown), Christine Terré, Sylvie Castaigné, Sophie Rigaudeau, Philippe Rousselot, Stéphane de Botton	16
10	Characterization of Missense Mutations and Large Deletions in the ALPL Gene by Sequencing and Quantitative Multiplex PCR of Short Fragments 2006 ·Genetic Testing ·Marc Spentchian, Isabelle Brun‐Heath, A. Taillandier, Delphine Fauvert, Jean‐Louis Serre, Brigitte Simon‐Bouy, Filipa Carvalho, (unknown), Sarju Mehta, Grit Müller, Saskia A.J. Lesnik Oberstein, Gönül Oğur, Saba Sharif, Étienne Mornet	20
11	Evidence of a founder effect for the tissue-nonspecific alkaline phosphatase (TNSALP) gene E174K mutation in hypophosphatasia patients 2002 ·European Journal of Human Genetics ·Muriel Hérasse, Marc Spentchian, A. Taillandier, Étienne Mornet	27
12	Time course of troponin I, myoglobin, and cardiac enzyme release after electrical cardioversion 1996 ·The American Journal of Cardiology ·Jean‐Louis Georges, Marc Spentchian, (unknown), (unknown), (unknown), B. Livarek, (unknown)	36

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact